New pill aims to halt Vision-Threatening eye inflammation

NCT ID NCT06431373

Ongoing Disease control Sponsor: Priovant Therapeutics, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an oral medication called brepocitinib is safe and effective for controlling active uveitis, a type of serious eye inflammation that can lead to vision loss. It will involve about 371 adults with intermediate, posterior, or panuveitis. Participants will be randomly assigned to receive either the study drug or a placebo pill to compare how well the drug prevents the inflammation from getting worse over nearly a year.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Trial Site

Phoenix, Arizona, 85020, United States
Clinical Trial Site

Phoenix, Arizona, 85054, United States
Clinical Trial Site

Bakersfield, California, 93309, United States
Clinical Trial Site

Beverly Hills, California, 90211, United States
Clinical Trial Site

Fullerton, California, 92835, United States
Clinical Trial Site

Irvine, California, 92697, United States
Clinical Trial Site

La Jolla, California, 92093, United States
Clinical Trial Site

Los Angeles, California, 90033, United States
Clinical Trial Site

Los Angeles, California, 90095, United States
Clinical Trial Site

Modesto, California, 95356, United States
Clinical Trial Site

Sacramento, California, 92825, United States
Clinical Trial Site

Aurora, Colorado, 80045, United States
Clinical Trial Site

Denver, Colorado, 80246, United States
Clinical Trial Site

Fort Lauderdale, Florida, 33308, United States
Clinical Trial Site

St. Petersburg, Florida, 33711, United States
Clinical Trial Site

Chicago, Illinois, 60637, United States
Clinical Trial Site

Oak Park, Illinois, 60304, United States
Clinical Trial Site

Carmel, Indiana, 46290, United States
Clinical Trial Site

Prairie Village, Kansas, 66208, United States
Clinical Trial Site

Baltimore, Maryland, 21287, United States
Clinical Trial Site

Boston, Massachusetts, 02114, United States
Clinical Trial Site

Waltham, Massachusetts, 02451, United States
Clinical Trial Site

Ann Arbor, Michigan, 48105, United States
Clinical Trial Site

Detroit, Michigan, 48201, United States
Clinical Trial Site

Detroit, Michigan, 48202, United States
Clinical Trial Site

Minneapolis, Minnesota, 55455, United States
Clinical Trial Site

Rochester, Minnesota, 55905, United States
Clinical Trial Site

St Louis, Missouri, 63108, United States
Clinical Trial Site

Omaha, Nebraska, 68105, United States
Clinical Trial Site

Palisades Park, New Jersey, 07650, United States
Clinical Trial Site

Rochester, New York, 14642, United States
Clinical Trial Site

Durham, North Carolina, 27705, United States
Clinical Trial Site

Winston-Salem, North Carolina, 27157, United States
Clinical Trial Site

Cleveland, Ohio, 44106, United States
Clinical Trial Site

Cleveland, Ohio, 44195, United States
Clinical Trial Site

Columbus, Ohio, 43212, United States
Clinical Trial Site

Portland, Oregon, 97221, United States
Clinical Trial Site

Portland, Oregon, 97239, United States
Clinical Trial Site

Erie, Pennsylvania, 16507, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19107, United States
Clinical Trial Site

Philadelphia, Pennsylvania, 19141, United States
Clinical Trial Site

Greenville, South Carolina, 29605, United States
Clinical Trial Site

Nashville, Tennessee, 37232, United States
Clinical Trial Site

Austin, Texas, 78712, United States
Clinical Trial Site

Bellaire, Texas, 77401, United States
Clinical Trial Site

Dallas, Texas, 75390, United States
Clinical Trial Site

Houston, Texas, 77025, United States
Clinical Trial Site

Katy, Texas, 77494, United States
Clinical Trial Site

Plano, Texas, 75075, United States
Clinical Trial Site

Round Rock, Texas, 78681, United States
Clinical Trial Site

San Antonio, Texas, 78230, United States
Clinical Trial Site

Madison, Wisconsin, 53705, United States
Clinical Trial Site

Rosario, Santa Fe Province, 41076, Argentina
Clinical Trial Site

Buenos Aires, 41076, Argentina
Clinical Trial Site

Buenos Aires, C1015, Argentina
Clinical Trial Site

Buenos Aires, C1061AAE, Argentina
Clinical Trial Site

Buenos Aires, C1121, Argentina
Clinical Trial Site

Sydney, New South Wales, 2000, Australia
Clinical Trial Site

East Melbourne, Victoria, 3002, Australia
Clinical Trial Site

Nedlands, Western Australia, 6009, Australia
Clinical Trial Site

Linz, 04020, Austria
Clinical Trial Site

Leuven, VI-Brabant, 3000, Belgium
Clinical Trial Site

Prague, 128 08, Czechia
Clinical Trial Site

Mannheim, Baden-Wurttemberg, 68167, Germany
Clinical Trial Site

Bonn, North Rhine-Westphalia, 53127, Germany
Clinical Trial Site

Düsseldorf, North Rhine-Westphalia, 40225, Germany
Clinical Trial Site

Münster, North Rhine-Westphalia, 48145, Germany
Clinical Trial Site

Münster, North Rhine-Westphalia, 48149, Germany
Clinical Trial Site

Kiel, 24105, Germany
Clinical Trial Site

Mainz, 55131, Germany
Clinical Trial Site

Thessaloniki, 54622, Greece
Clinical Trial Site

Pécs, Baranya, 07623, Hungary
Clinical Trial Site

Debrecen, Hajdú-Bihar, 04032, Hungary
Clinical Trial Site

Budapest, Pest County, 01085, Hungary
Clinical Trial Site

Budapest, 01133, Hungary
Clinical Trial Site

Ashkelon, 7830604, Israel
Clinical Trial Site

Haifa, 3109601, Israel
Clinical Trial Site

Haifa, 3434104, Israel
Clinical Trial Site

Holon, 58101, Israel
Clinical Trial Site

Jerusalem, 9013102, Israel
Clinical Trial Site

Jerusalem, 9112001, Israel
Clinical Trial Site

Kfar Saba, 4428164, Israel
Clinical Trial Site

Poria – Neve Oved, 1528801, Israel
Clinical Trial Site

Tel Aviv, 6423906, Israel
Clinical Trial Site

Tel Aviv, 69710, Israel
Clinical Trial Site

Perugia, Umbria, 06129, Italy
Clinical Trial Site

Milan, Italy
Clinical Trial Site

Reggio Emilia, 42123, Italy
Clinical Trial Site

Roma, 00184, Italy
Clinical Trial Site

Barcelona, Catalonia, 08035, Spain
Clinical Trial Site

Barcelona, 08028, Spain
Clinical Trial Site

Madrid, 28-046, Spain
Clinical Trial Site

Madrid, 28040, Spain
Clinical Trial Site

Valladolid, 47011, Spain
Clinical Trial Site

London, England, EC1V 2PD, United Kingdom
Clinical Trial Site

London, England, SE1 7EH, United Kingdom
Clinical Trial Site

Maidstone, Kent, ME169QQ, United Kingdom
Clinical Trial Site

Middlesbrough, North Yorkshire, TS4 3BW, United Kingdom
Clinical Trial Site

Oxford, Oxfordshire, OX3 9DU, United Kingdom
Clinical Trial Site

Sheffield, South Yorkshire, S10 2JF, United Kingdom
Clinical Trial Site

Birmingham, West Midlands, B18 7QH, United Kingdom
Clinical Trial Site

Bradford, Yorkshire, BD9 6TB, United Kingdom
Clinical Trial Site

Birmingham, B1S 2GW, United Kingdom
Clinical Trial Site

Bristol, BS1 2LX, United Kingdom
Clinical Trial Site

Liverpool, L7 8XP, United Kingdom
Clinical Trial Site

Manchester, M13 9WL, United Kingdom
NYU Langone Health

New York, New York, 10017, United States

Conditions

Explore the condition pages connected to this study.

UVEITIS UVEITIS, INTERMEDIATE UVEITIS, POSTERIOR